<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-11-17" updated="2019-12-02">
  <drugbank-id primary="true">DB09328</drugbank-id>
  <name>Vayarin</name>
  <description>Vayarin is a prescription medical food for the clinical dietary management of certain lipid imbalances blamed to be associated with attention deficit hyperactivity disorder (ADHD) in children. Vayarin contains _Lipirinen_, a proprietary composition containing phosphatidylserine-omega 3, EPA (eicosapentaenoic acid), and docosahexaenoic acid (DHA) [L1500, L14501, L1510]. Vayarin is currently available only by prescription in the USA [L1502].  This drug has also been used for management of hypertriglyceridemia [L1503].&#13;
&#13;
Vayarin is an orally administered prescription medical food for the clinical dietary management of complex lipid imbalances thought to be associated with ADHD. Vayarin is a specially formulated and designed to address the distinct, previously determined lipid nutritional requirements of children with ADHD, the dietary management of which cannot be achieved with lifestyle modification [L1502].&#13;
&#13;
Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503]. Approximately 60% of the users who completed 12 weeks of therapy reported subjective benefits from treatment. A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study. Cost of the drug and patient aversion to the taste of Vayarin were significant reasons for therapy failure [L1502].</description>
  <cas-number/>
  <unii/>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32047</ref-id>
        <pubmed-id>10984109</pubmed-id>
        <citation>Hamilton L, Greiner R, Salem N Jr, Kim HY: n-3 fatty acid deficiency decreases phosphatidylserine accumulation selectively in neuronal tissues. Lipids. 2000 Aug;35(8):863-9.</citation>
      </article>
      <article>
        <ref-id>A32049</ref-id>
        <pubmed-id>23312676</pubmed-id>
        <citation>Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, Richter Y, Zaaroor-Regev D, Manor Y, Weizman A: Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: a double-blind placebo-controlled trial followed by an open-label extension. Eur Psychiatry. 2013 Aug;28(6):386-91. doi: 10.1016/j.eurpsy.2012.11.001. Epub 2013 Jan 9.</citation>
      </article>
      <article>
        <ref-id>A32050</ref-id>
        <pubmed-id>12608694</pubmed-id>
        <citation>Mozzi R, Buratta S, Goracci G: Metabolism and functions of phosphatidylserine in mammalian brain. Neurochem Res. 2003 Feb;28(2):195-214.</citation>
      </article>
      <article>
        <ref-id>A32055</ref-id>
        <pubmed-id>14285489</pubmed-id>
        <citation>WISE EM Jr, ELWYN D: RATES OF REACTIONS INVOLVED IN PHOSPHATIDE SYNTHESIS IN LIVER AND SMALL INTESTINE OF INTACT RATS. J Biol Chem. 1965 Apr;240:1537-48.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L1500</ref-id>
        <title>Efficacy Study of Vayarin in Children With Autism and Comorbid Attention Deficit Hyperactivity Disorder (ADHD)</title>
        <url>https://clinicaltrials.gov/ct2/show/NCT03115671</url>
      </link>
      <link>
        <ref-id>L1501</ref-id>
        <title>Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment (VAYA-fMRI)</title>
        <url>https://clinicaltrials.gov/ct2/show/NCT02473419</url>
      </link>
      <link>
        <ref-id>L1502</ref-id>
        <title>mproved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of VayarinÂ®, a Multi-Year, Real-World Retrospective Study</title>
        <url>https://globenewswire.com/news-release/2017/01/10/904861/0/en/Improved-Academic-Performance-and-Medication-Rebound-in-Patients-with-ADHD-Following-the-Use-of-Vayarin-a-Multi-Year-Real-World-Retrospective-Study.html</url>
      </link>
      <link>
        <ref-id>L1503</ref-id>
        <title>Pharmacokinetics Basics- Absorption, Distribution, Metabolism and Excretion</title>
        <url>https://www.ndrugs.com/?s=vayarin&amp;t=actions</url>
      </link>
      <link>
        <ref-id>L1504</ref-id>
        <title>Vaya Direct</title>
        <url>https://vayadirect.com</url>
      </link>
      <link>
        <ref-id>L1506</ref-id>
        <title>Vayarin product label</title>
        <url>https://vayadirect.com/wp-content/uploads/2018/01/RIN_PI_PA-Final_new-slip.pdf</url>
      </link>
      <link>
        <ref-id>L1507</ref-id>
        <title>FDA label PS</title>
        <url>https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm513828.pdf</url>
      </link>
      <link>
        <ref-id>L1508</ref-id>
        <title>Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of  EPA, DPA and DHA</title>
        <url>https://www.frontiersin.org/articles/10.3389/fnagi.2015.00052/</url>
      </link>
      <link>
        <ref-id>L1510</ref-id>
        <title>Drug Insert Vayarin</title>
        <url>http://122.179.130.16/~vayarin/wp-content/uploads/2015/02/vayarin-60ct-outsert-ver-9.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>ADHD in children,  hypertriglyceridemia [L1502, L1503].</indication>
  <pharmacodynamics>Compared to healthy children of the same age, children with ADHD have lower circulating concentrations of omega-3 long-chain polyunsaturated fatty acid. These lipids, found in the brain, play an essential role in central nervous system development and function. It has been reported that omega-3 fatty acid deficiency is directly associated with decreased brain phosphatidylserine, which is mainly in the form of phosphatidylserine-Omega-3 (Ps-Omega-3) [L1500, L1502].&#13;
&#13;
PS-Omega-3 such as Vayarin, are believed to be essential in the functioning of neuronal cell membranes, in activities such as signal transduction, secretory vesicle release, cell-to-cell communication, and cell growth regulation. Reduced levels of PS-Omega-3 and omega-3 fatty acids may play an important role in the pathogenesis of ADHD and other neuronal disorders. Vayarin is a proprietary lipid composition of phosphatidylserine-Omega-3 (PS-Omega-3), enriched with eicosapentaenoic acid. This formula has been designed to provide the essential lipids to brain tissues in order to support and maintain proper brain function. Additionally, the enrichment of EPA in the Vayarin medical food allows for better regulation of lipids and acts on the specific imbalances that are thought to be associated with ADHD [A32047, L1500].&#13;
&#13;
Current studies are underway for the efficacy of Vayarin in ADHD and autism spectrum disorder co-morbidity [L1500].  In addition, studies of Vayarin in adults using MRI to study alterations in radiographic findings are currently underway, allowing for other possible benefits of this medication [L1501].&#13;
&#13;
</pharmacodynamics>
  <mechanism-of-action>Phosphatidylserine (PS) in the mammalian nervous system, containing high levels of omega-3 fatty acids, has been implicated in numerous membrane-associated functions, such as maintaining the integrity of cell membranes, cell excitability and cell-to-cell recognition and communication. While the exact mechanism by which this medical food exerts its effects is not fully understood, PS has been found to regulate important proteins in neuronal cell membranes, including sodium/calcium ATPase and protein kinase C, which perform crucial functions in many signal transduction pathways. Similarly, PS interacts with Raf-1 protein kinase [L1506] to promote a cascade of reactions that are believed to be involved in the survival of cells [L1506]. Additionally, PS has been found to influence neurotransmitter activity, such as the release of acetylcholine (Ach), dopamine, and noradrenaline. In addition, it is also thought to increase brain glucose concentrations [L1506]. Administration of specially processed formulations consisting of PS conjugated to omega-3 fatty acids was found to significantly increase DHA levels in the brain tissue of rats [L1506].  </mechanism-of-action>
  <toxicity>The safety phosphatidyl serine conjugated to omega-3 (PS-Omega-3) is supported by several pre-clinical studies. Multiple dose safety studies in rats and dogs showed that oral administration of PS-Omega-3 at doses up to 1000 mg/kg/day for up to 6 months was without any significant effects. Teratogenicity studies in rats demonstrate that when given at doses up to 200 mg/kg/day and in rabbits at doses up to 450 mg/kg/ day, Ps Omega-3 (the main component of this medical food) did not affect embryonic and fetal development. The mutagenic potential of PS-Omega-3 was investigated in several cell types and revealed no significant findings. In a micronucleus test, PS-Omega-3 was given to mice at total dosages of 30, 150 and 300 mg/kg in two equal doses separated by 24 hours. The results of the study did not demonstrate any evidence of mutagenic properties or incidence of bone marrow toxicity [L1506].&#13;
&#13;
In rats, Ld50 was greater than 5 mg/Kg for PS [L1506, L1508].</toxicity>
  <metabolism>Phospholipids can break down into various substrates or remain intact and absorbed in the circulatory system and cross the blood brain barrier. Following dietary ingestion of PS, fatty acids esterified to the PS molecule are hydrolyzed by pancreatic enzymes, forming lyso-PS and free fatty acids (FFA). After the lyso-PS is absorbed by the intestinal mucosa, it can be re-acylated into PS, while partially converted into other phospholipids. Phosphatidylserine and other phospholipids formed inside the enterocytes can either be transported in the lymphatic circulation as chylomicrons or in the hepatic circulation, and enter the systemic circulation for distribution across the body. Current evidence shows that ingested phosphatidylserine reaches the systemic circulation and is incorporated into the phospholipids pool as phosphatidylethanolamine and other metabolites [L1506, L1510].&#13;
&#13;
The omega-3 polyunsaturated fatty acid metabolism cycle begins with a series of desaturation, elongation and  Î²-oxidation reactions.  In a study of healthy volunteers and patients with hypertriglyceridemia, eicosapentaenoic acid, and DHA were absorbed when administered as ethyl esters orally. Omega-3-acids administered as ethyl esters (Vayarin) induced significant, dose-dependent increases in serum phospholipid eicosapentaenoic acid content, though increases in DHA content were less significant and not dose-dependent when administered as ethyl esters. Uptake of EPA and DHA into serum phospholipids in subjects treated with Vayarin was independent of age (&lt;49 years versus â¥49 years). Females were found to have more uptake of EPA into serum phospholipids than males [L1503].&#13;
&#13;
&#13;
The effect of a mixture of free fatty acids (FFA), EPA/DHA and their FFA-albumin conjugate on cytochrome P450-dependent monooxygenase activities was assessed in human liver microsomes. At the 23 Î¼M concentration, FFA resulted in a less than 32% inhibition of CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A. At the 23 Î¼M concentration, the FFA-albumin conjugate resulted in a less than 20% inhibition of CYP2A6, 2C19, 2D6, and 3A, with a 68% inhibition being seen for CYP2E1 [L1503].&#13;
&#13;
In healthy volunteers and in patients with hypertriglyceridemia (HTG), EPA and DHA were absorbed when administered as ethyl esters orally. Omega-3-acids administered as ethyl esters (Vayarin) induced significant, doseâdependent increases in serum phospholipid EPA content, though increases in DHA content were less marked and not dose-dependent when administered as ethyl esters. Uptake of EPA and DHA into serum phospholipids in subjects treated with Vayarin was independent of age (&lt;49 years vs. â¥49 years). Females tended to have more uptake of EPA into serum phospholipids than males. Pharmacokinetic data on Vayarin in children are not available [L1506, L1508].</metabolism>
  <absorption>Phosphatidylserine (the main component of this medical food) is an endogenous substance found in the human body.  This medication is metabolized mainly in the intestines by decarboxylases in the mucosal cells [L1506]. The bioavailability of the ingested PS is poorly demonstrated to extensive metabolism in the intestine before absorption, and due to the fact that PS is transported and rapidly converted into other endogenous constituents [L1507].&#13;
&#13;
In one study, after oral administration of Vayarin to rats, most of the isotope label recovered from blood samples remained as the parent compound, PS,  for up to 60 min after administration. After 24 h, metabolites were recovered from the blood, primarily as lysophosphatidylethanolamine and lysophosphatidylcholine. When radiolabeled PS was administered (orally or intraperitoneally) in animals, the radioactivity found in the urine was primarily metabolized (water soluble), whereas the 60-65% of fecal radioactivity was mainly associated with lipids. The major metabolite recovered in the feces was lysoPS after oral administration [L1507].</absorption>
  <half-life>About 2h [L1507]</half-life>
  <protein-binding/>
  <route-of-elimination>For all routes of administration, about 60% of the ingested PS is excreted in feces, while 10% is eliminated in the urine [L1506].</route-of-elimination>
  <volume-of-distribution/>
  <clearance>Mainly in the feces and urine [L1506].</clearance>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Phosphatidylserine, DHA, and EPA</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Cytochrome P-450 CYP2E1 Inhibitors</category>
      <mesh-id>D065691</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The metabolism of Ethosuximide can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The metabolism of Quinidine can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>Vayarin may increase the hepatotoxic activities of Acetaminophen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Vayarin may increase the hepatotoxic activities of Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>The metabolism of Enflurane can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The metabolism of Trimethadione can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The metabolism of Chlorzoxazone can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The metabolism of Isoflurane can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The metabolism of Ethanol can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The metabolism of Methoxyflurane can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The metabolism of Halothane can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The metabolism of Sevoflurane can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The metabolism of Nilvadipine can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06728</drugbank-id>
      <name>Aniline</name>
      <description>The metabolism of Aniline can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The metabolism of Benzyl alcohol can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The metabolism of Felbamate can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The metabolism of Cenobamate can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The metabolism of Tamoxifen can be decreased when combined with Vayarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The metabolism of Carvedilol can be decreased when combined with Vayarin.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910439</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Vayarin</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes>
    <enzyme position="1">
      <id>BE0003533</id>
      <name>Cytochrome P450 2E1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L1503</ref-id>
            <title>Pharmacokinetics Basics- Absorption, Distribution, Metabolism and Excretion</title>
            <url>https://www.ndrugs.com/?s=vayarin&amp;t=actions</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05181" source="Swiss-Prot">
        <name>Cytochrome P450 2E1</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.</specific-function>
        <gene-name>CYP2E1</gene-name>
        <locus>10q24.3-qter</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.22</theoretical-pi>
        <molecular-weight>56848.42</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2631</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J02625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181360</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1330</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05181</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2E1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.13.-</synonym>
          <synonym>4-nitrophenol 2-hydroxylase</synonym>
          <synonym>CYP2E</synonym>
          <synonym>CYPIIE1</synonym>
          <synonym>Cytochrome P450-J</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012460|Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012461|Cytochrome P450 2E1 (CYP2E1)
ATGTCTGCCCTCGGAGTCACCGTGGCCCTGCTGGTGTGGGCGGCCTTCCTCCTGCTGGTG
TCCATGTGGAGGCAGGTGCACAGCAGCTGGAATCTGCCCCCAGGCCCTTTCCCGCTTCCC
ATCATCGGGAACCTCTTCCAGTTGGAATTGAAGAATATTCCCAAGTCCTTCACCCGGTTG
GCCCAGCGCTTCGGGCCGGTGTTCACGCTGTACGTGGGCTCGCAGCGCATGGTGGTGATG
CACGGCTACAAGGCGGTGAAGGAAGCGCTGCTGGACTACAAGGACGAGTTCTCGGGCAGA
GGCGACCTCCCCGCGTTCCATGCGCACAGGGACAGGGGAATCATTTTTAATAATGGACCT
ACCTGGAAGGACATCCGGCGGTTTTCCCTGACCACCCTCCGGAACTATGGGATGGGGAAA
CAGGGCAATGAGAGCCGGATCCAGAGGGAGGCCCACTTCCTGCTGGAAGCACTCAGGAAG
ACCCAAGGCCAGCCTTTCGACCCCACCTTCCTCATCGGCTGCGCGCCCTGCAACGTCATA
GCCGACATCCTCTTCCGCAAGCATTTTGACTACAATGATGAGAAGTTTCTAAGGCTGATG
TATTTGTTTAATGAGAACTTCCACCTACTCAGCACTCCCTGGCTCCAGCTTTACAATAAT
TTTCCCAGCTTTCTACACTACTTGCCTGGAAGCCACAGAAAAGTCATAAAAAATGTGGCT
GAAGTAAAAGAGTATGTGTCTGAAAGGGTGAAGGAGCACCATCAATCTCTGGACCCCAAC
TGTCCCCGGGACCTCACCGACTGCCTGCTCGTGGAAATGGAGAAGGAAAAGCACAGTGCA
GAGCGCTTGTACACAATGGACGGTATCACCGTGACTGTGGCCGACCTGTTCTTTGCGGGG
ACAGAGACCACCAGCACAACTCTGAGATATGGGCTCCTGATTCTCATGAAATACCCTGAG
ATCGAAGAGAAGCTCCATGAAGAAATTGACAGGGTGATTGGGCCAAGCCGAATCCCTGCC
ATCAAGGATAGGCAAGAGATGCCCTACATGGATGCTGTGGTGCATGAGATTCAGCGGTTC
ATCACCCTCGTGCCCTCCAACCTGCCCCATGAAGCAACCCGAGACACCATTTTCAGAGGA
TACCTCATCCCCAAGGGCACAGTCGTAGTGCCAACTCTGGACTCTGTTTTGTATGACAAC
CAAGAATTTCCTGATCCAGAAAAGTTTAAGCCAGAACACTTCCTGAATGAAAATGGAAAG
TTCAAGTACAGTGACTATTTCAAGCCATTTTCCACAGGAAAACGAGTGTGTGCTGGAGAA
GGCCTGGCTCGCATGGAGTTGTTTCTTTTGTTGTGTGCCATTTTGCAGCATTTTAATTTG
AAGCCTCTCGTTGACCCAAAGGATATCGACCTCAGCCCTATACATATTGGGTTTGGCTGT
ATCCCACCACGTTACAAACTCTGTGTCATTCCCCGCTCATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intrinsic component of endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organonitrogen compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ozone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>triglyceride metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="2">
      <id>BE0000888</id>
      <name>Fatty acid desaturase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L1508</ref-id>
            <title>Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of  EPA, DPA and DHA</title>
            <url>https://www.frontiersin.org/articles/10.3389/fnagi.2015.00052/</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O60427" source="Swiss-Prot">
        <name>Fatty acid desaturase 1</name>
        <general-function>Oxidoreductase activity</general-function>
        <specific-function>Isoform 2 does not exhibit any catalytic activity toward 20:3n-6, but it may enhance FADS2 activity (By similarity). Isoform 1 is a component of a lipid metabolic pathway that catalyzes biosynthesis of highly unsaturated fatty acids (HUFA) from precursor essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3). Catalyzes the desaturation of dihomo-gamma-linoleic acid (DHGLA) (20:3n-6) and eicosatetraenoic acid (20:4n-3) to generate arachidonic acid (AA) (20:4n-6) and eicosapentaenoic acid (EPA)(20:5n-3), respectively.</specific-function>
        <gene-name>FADS1</gene-name>
        <locus/>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>122-142
146-170
268-288
306-326</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.15</theoretical-pi>
        <molecular-weight>51963.945</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3574</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DKFZp762M2311</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AC004770</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3169158</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O60427</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FADS1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.19.-</synonym>
          <synonym>D5D</synonym>
          <synonym>Delta-5 desaturase</synonym>
          <synonym>Delta(5) desaturase</synonym>
          <synonym>Delta(5) fatty acid desaturase</synonym>
          <synonym>FADSD5</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001770|Fatty acid desaturase 1
MAPDPVAAETAAQGPTPRYFTWDEVAQRSGCEERWLVIDRKVYNISEFTRRHPGGSRVIS
HYAGQDATDPFVAFHINKGLVKKYMNSLLIGELSPEQPSFEPTKNKELTDEFRELRATVE
RMGLMKANHVFFLLYLLHILLLDGAAWLTLWVFGTSFLPFLLCAVLLSAVQAQAGWLQHD
FGHLSVFSTSKWNHLLHHFVIGHLKGAPASWWNHMHFQHHAKPNCFRKDPDINMHPFFFA
LGKILSVELGKQKKKYMPYNHQHKYFFLIGPPALLPLYFQWYIFYFVIQRKKWVDLAWMI
TFYVRFFLTYVPLLGLKAFLGLFFIVRFLESNWFVWVTQMNHIPMHIDHDRNMDWVSTQL
QATCNVHKSAFNDWFSGHLNFQIEHHLFPTMPRHNYHKVAPLVQSLCAKHGIEYQSKPLL
SAFADIIHSLKESGQLWLDAYLHQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010626|Fatty acid desaturase 1 (FADS1)
ATGGGAACGCGCGCTGCGAGGCCCGCCGGTCTGCCCTGCGGTGCTGAAAACCCGGCGCGC
AGGCGGCTGGCTCTGGGCGCGCGCCAGCAAATCCACTCCTGGAGCCCGCGGACCCCGAGC
ACGCGCCTGACAGCCCCTGCTGGCCCGGCGCGCGGCGTCGCCAGGCCAGCTATGGCCCCC
GACCCGGTGGCCGCCGAGACCGCGGCTCAGGGACCTACCCCGCGCTACTTCACCTGGGAC
GAGGTGGCCCAGCGCTCAGGGTGCGAGGAGCGGTGGCTAGTGATCGACCGTAAGGTGTAC
AACATCAGCGAGTTCACCCGCCGGCATCCAGGGGGCTCCCGGGTCATCAGCCACTACGCC
GGGCAGGATGCCACGGATCCCTTTGTGGCCTTCCACATCAACAAGGGCCTTGTGAAGAAG
TATATGAACTCTCTCCTGATTGGAGAACTGTCTCCAGAGCAGCCCAGCTTTGAGCCCACC
AAGAATAAAGAGCTGACAGATGAGTTCCGGGAGCTGCGGGCCACAGTGGAGCGGATGGGG
CTCATGAAGGCCAACCATGTCTTCTTCCTGCTGTACCTGCTGCACATCTTGCTGCTGGAT
GGTGCAGCCTGGCTCACCCTTTGGGTCTTTGGGACGTCCTTTTTGCCCTTCCTCCTCTGT
GCGGTGCTGCTCAGTGCAGTTCAGGCCCAGGCTGGCTGGCTGCAGCATGACTTTGGGCAC
CTGTCGGTCTTCAGCACCTCAAAGTGGAACCATCTGCTACATCATTTTGTGATTGGCCAC
CTGAAGGGGGCCCCCGCCAGTTGGTGGAACCACATGCACTTCCAGCACCATGCCAAGCCC
AACTGCTTCCGCAAAGACCCAGACATCAACATGCATCCCTTCTTCTTTGCCTTGGGGAAG
ATCCTCTCTGTGGAGCTTGGGAAACAGAAGAAAAAATATATGCCGTACAACCACCAGCAC
AAATACTTCTTCCTAATTGGGCCCCCAGCCTTGCTGCCTCTCTACTTCCAGTGGTATATT
TTCTATTTTGTTATCCAGCGAAAGAAGTGGGTGGACTTGGCCTGGATGATTACCTTCTAC
GTCCGCTTCTTCCTCACTTATGTGCCACTATTGGGGCTGAAAGCCTTCCTGGGCCTTTTC
TTCATAGTCAGGTTCCTGGAAAGCAACTGGTTTGTGTGGGTGACACAGATGAACCATATT
CCCATGCACATTGATCATGACCGGAACATGGACTGGGTTTCCACCCAGCTCCAGGCCACA
TGCAATGTCCACAAGTCTGCCTTCAATGACTGGTTCAGTGGACACCTCAACTTCCAGATT
GAGCACCATCTTTTTCCCACGATGCCTCGACACAATTACCACAAAGTGGCTCCCCTGGTG
CAGTCCTTGTGTGCCAAGCATGGCATAGAGTACCAGTCCAAGCCCCTGCTGTCAGCCTTC
GCCGACATCATCCACTCACTAAAGGAGTCAGGGCAGCTCTGGCTAGATGCCTATCTTCAC
CAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00173</identifier>
            <name>Cyt-b5</name>
          </pfam>
          <pfam>
            <identifier>PF00487</identifier>
            <name>FA_desaturase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>C-5 sterol desaturase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alpha-linolenic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>icosanoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>linoleic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>unsaturated fatty acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>unsaturated fatty acid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="3">
      <id>BE0002247</id>
      <name>Elongation of very long chain fatty acids protein 4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L1506</ref-id>
            <title>Vayarin product label</title>
            <url>https://vayadirect.com/wp-content/uploads/2018/01/RIN_PI_PA-Final_new-slip.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9GZR5" source="Swiss-Prot">
        <name>Elongation of very long chain fatty acids protein 4</name>
        <general-function>Transferase activity</general-function>
        <specific-function>Catalyzes the first and rate-limiting reaction of the four that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. Condensing enzyme that specifically elongates C24:0 and C26:0 acyl-CoAs. May participate to the production of saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. May play a critical role in early brain and skin development.</specific-function>
        <gene-name>ELOVL4</gene-name>
        <locus>6q14</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>42-62
78-98
127-147
165-185
188-208
217-237
247-267</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.86</theoretical-pi>
        <molecular-weight>36828.905</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:14415</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ELOVL4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF279654</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>12044051</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9GZR5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ELOV4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.3.1.199</synonym>
          <synonym>3-keto acyl-CoA synthase ELOVL4</synonym>
          <synonym>ELOVL FA elongase 4</synonym>
          <synonym>ELOVL fatty acid elongase 4</synonym>
          <synonym>Very long chain 3-ketoacyl-CoA synthase 4</synonym>
          <synonym>Very long chain 3-oxoacyl-CoA synthase 4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019253|Elongation of very long chain fatty acids protein 4
MGLLDSEPGSVLNVVSTALNDTVEFYRWTWSIADKRVENWPLMQSPWPTLSISTLYLLFV
WLGPKWMKDREPFQMRLVLIIYNFGMVLLNLFIFRELFMGSYNAGYSYICQSVDYSNNVH
EVRIAAALWWYFVSKGVEYLDTVFFILRKKNNQVSFLHVYHHCTMFTLWWIGIKWVAGGQ
AFFGAQLNSFIHVIMYSYYGLTAFGPWIQKYLWWKRYLTMLQLIQFHVTIGHTALSLYTD
CPFPKWMHWALIAYAISFIFLFLNFYIRTYKEPKKPKAGKTAMNGISANGVSKSEKQLMI
ENGKKQKNGKAKGD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019254|Elongation of very long chain fatty acids protein 4 (ELOVL4)
ATGGGGCTCCTGGACTCGGAGCCGGGTAGTGTCCTAAACGTAGTGTCCACGGCACTCAAC
GACACGGTAGAGTTCTACCGCTGGACCTGGTCCATCGCAGATAAGCGTGTGGAAAATTGG
CCTCTGATGCAGTCTCCTTGGCCTACACTAAGTATAAGCACTCTTTATCTCCTGTTTGTG
TGGCTGGGTCCAAAATGGATGAAGGACCGAGAACCTTTTCAGATGCGTCTAGTGCTCATT
ATCTATAATTTTGGGATGGTTTTGCTTAACCTCTTTATCTTCAGAGAGTTATTCATGGGA
TCATATAATGCGGGATATAGCTATATTTGCCAGAGTGTGGATTATTCTAATAATGTTCAT
GAAGTCAGGATAGCTGCTGCTCTGTGGTGGTACTTTGTATCTAAAGGAGTTGAGTATTTG
GACACAGTGTTTTTTATTCTGAGAAAGAAAAACAACCAAGTTTCTTTCCTTCATGTGTAT
CATCACTGTACGATGTTTACCTTGTGGTGGATTGGAATTAAGTGGGTTGCAGGAGGACAA
GCATTTTTTGGAGCCCAGTTGAATTCCTTTATCCATGTGATTATGTACTCATACTATGGG
TTAACTGCATTTGGCCCATGGATTCAGAAATATCTTTGGTGGAAACGATACCTGACTATG
TTGCAACTGATTCAATTCCATGTGACCATTGGGCACACGGCACTGTCTCTTTACACTGAC
TGCCCCTTCCCCAAATGGATGCACTGGGCTCTAATTGCCTATGCAATCAGCTTCATATTT
CTCTTTCTTAACTTCTACATTCGGACATACAAAGAGCCTAAGAAACCAAAAGCTGGAAAA
ACAGCCATGAATGGTATTTCAGCAAATGGTGTGAGCAAATCAGAAAAACAACTCATGATA
GAAAATGGAAAAAAGCAGAAAAATGGAAAAGCAAAAGGAGATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01151</identifier>
            <name>ELO</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled photoreceptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid elongation, saturated fatty acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-chain fatty-acyl-CoA biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>triglyceride biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>very long-chain fatty acid biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="4">
      <id>BE0004135</id>
      <name>Peroxisomal acyl-coenzyme A oxidase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185579</ref-id>
            <pubmed-id>25954194</pubmed-id>
            <citation>Dyall SC: Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015 Apr 21;7:52. doi: 10.3389/fnagi.2015.00052. eCollection 2015.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q15067" source="Swiss-Prot">
        <name>Peroxisomal acyl-coenzyme A oxidase 1</name>
        <general-function>Receptor binding</general-function>
        <specific-function>Catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-CoAs. Isoform 1 shows highest activity against medium-chain fatty acyl-CoAs and activity decreases with increasing chain length. Isoform 2 is active against a much broader range of substrates and shows activity towards very long-chain acyl-CoAs. Isoform 2 is twice as active as isoform 1 against 16-hydroxy-palmitoyl-CoA and is 25% more active against 1,16-hexadecanodioyl-CoA.</specific-function>
        <gene-name>ACOX1</gene-name>
        <locus>17q24-q25|17q25.1</locus>
        <cellular-location>Peroxisome</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.29</theoretical-pi>
        <molecular-weight>74423.035</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:119</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U07866</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>495475</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q15067</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACOX1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.3.3.6</synonym>
          <synonym>ACOX</synonym>
          <synonym>AOX</synonym>
          <synonym>Palmitoyl-CoA oxidase</synonym>
          <synonym>SCOX</synonym>
          <synonym>Straight-chain acyl-CoA oxidase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007874|Peroxisomal acyl-coenzyme A oxidase 1
MNPDLRRERDSASFNPELLTHILDGSPEKTRRRREIENMILNDPDFQHEDLNFLTRSQRY
EVAVRKSAIMVKKMREFGIADPDEIMWFKKLHLVNFVEPVGLNYSMFIPTLLNQGTTAQK
EKWLLSSKGLQIIGTYAQTEMGHGTHLRGLETTATYDPETQEFILNSPTVTSIKWWPGGL
GKTSNHAIVLAQLITKGKCYGLHAFIVPIREIGTHKPLPGITVGDIGPKFGYDEIDNGYL
KMDNHRIPRENMLMKYAQVKPDGTYVKPLSNKLTYGTMVFVRSFLVGEAARALSKACTIA
IRYSAVRHQSEIKPGEPEPQILDFQTQQYKLFPLLATAYAFQFVGAYMKETYHRINEGIG
QGDLSELPELHALTAGLKAFTSWTANTGIEACRMACGGHGYSHCSGLPNIYVNFTPSCTF
EGENTVMMLQTARFLMKSYDQVHSGKLVCGMVSYLNDLPSQRIQPQQVAVWPTMVDINSP
ESLTEAYKLRAARLVEIAAKNLQKEVIHRKSKEVAWNLTSVDLVRASEAHCHYVVVKLFS
EKLLKIQDKAIQAVLRSLCLLYSLYGISQNAGDFLQGSIMTEPQITQVNQRVKELLTLIR
SDAVALVDAFDFQDVTLGSVLGRYDGNVYENLFEWAKNSPLNKAEVHESYKHLKSLQSKL
</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020740|Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1)
ATGATCCTGAACGACCCAGACTTCCAGCATGAGGACTTGAACTTCCTCACTCGCAGCCAG
CGTTATGAGGTGGCTGTCAGGAAAAGTGCCATCATGGTGAAGAAGATGAGGGAGTTTGGC
ATCGCTGACCCTGATGAAATTATGTGGTTTAAAAATTTTGTGCACCGAGGGCGGCCTGAG
CCTCTGGATCTTCACTTGGGCATGTTCCTGCCCACCTTGCTTCACCAGGCAACTGCGGAG
CAGCAGGAGCGCTTCTTCATGCCCGCCTGGAACTTGGAGATCATTGGCACTTATGCCCAG
ACAGAGATGGGTCATGGAACTCACCTTCGAGGCTTGGAAACCACAGCCACGTATGACCCT
GAAACCCAGGAGTTCATTCTCAACAGTCCTACTGTGACCTCCATTAAATGGTGGCCTGGT
GGGCTTGGAAAGACTTCAAATCATGCAATAGTTCTTGCCCAGCTCATCACTAAGGGGAAA
TGCTATGGATTACATGCCTTTATCGTACCTATTCGTGAAATCGGGACCCATAAGCCTTTG
CCAGGAATTACCGTTGGTGACATCGGCCCCAAATTTGGTTATGATGAGATAGACAATGGC
TACCTCAAAATGGACAACCATCGTATTCCCAGAGAAAACATGCTGATGAAGTATGCCCAG
GTGAAGCCTGATGGCACATACGTGAAACCGCTGAGTAACAAGCTGACTTACGGGACCATG
GTGTTTGTCAGGTCCTTCCTTGTGGGAGAAGCTGCTCGGGCTCTGTCTAAGGCGTGCACC
ATTGCCATCCGATACAGCGCTGTGAGGCACCAGTCTGAAATCAAGCCAGGTGAACCAGAA
CCACAGATTTTGGATTTTCAAACCCAGCAGTATAAACTCTTTCCACTCCTGGCCACTGCC
TATGCCTTCCAGTTTGTGGGCGCATACATGAAGGAGACCTATCACCGGATTAACGAAGGC
ATTGGTCAAGGGGACCTGAGTGAACTGCCTGAGCTTCATGCCCTCACCGCTGGACTGAAG
GCTTTCACCTCCTGGACTGCAAACACTGGCATTGAAGCATGTCGGATGGCTTGTGGTGGG
CATGGCTATTCTCATTGCAGTGGTCTTCCAAATATTTATGTCAATTTCACCCCAAGCTGT
ACCTTTGAGGGAGAAAACACTGTCATGATGCTCCAGACGGCTAGGTTCCTGATGAAAAGT
TATGATCAGGTGCACTCAGGAAAGTTGGTGTGTGGCATGGTGTCCTATTTGAACGACCTG
CCCAGTCAGCGCATCCAGCCACAGCAGGTAGCAGTCTGGCCAACCATGGTGGATATCAAC
AGCCCCGAAAGCCTAACCGAAGCATATAAACTCCGTGCAGCCAGATTAGTAGAAATTGCT
GCAAAAAACCTTCAAAAAGAAGTGATTCACAGAAAAAGCAAGGAGGTAGCTTGGAACCTA
ACTTCTGTTGACCTTGTTCGAGCAAGTGAGGCACATTGCCACTATGTGGTAGTTAAGCTC
TTTTCAGAAAAACTCCTCAAAATTCAAGATAAAGCCATTCAAGCTGTCTTAAGGAGTTTA
TGTCTGCTGTATTCTCTGTATGGAATCAGTCAGAACGCGGGGGATTTCCTTCAGGGGAGC
ATCATGACAGAGCCTCAGATTACACAAGTAAACCAGCGTGTAAAGGAGTTACTCACTCTG
ATTCGCTCAGATGCTGTTGCTTTGGTTGATGCATTTGATTTTCAGGATGTGACACTTGGC
TCTGTGCTTGGCCGCTATGATGGGAATGTGTATGAAAACTTGTTTGAGTGGGCTAAGAAC
TCCCCACTGAACAAAGCAGAGGTCCACGAATCTTACAAGCACCTGAAGTCACTGCAGTCC
AAGCTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02770</identifier>
            <name>Acyl-CoA_dh_M</name>
          </pfam>
          <pfam>
            <identifier>PF01756</identifier>
            <name>ACOX</name>
          </pfam>
          <pfam>
            <identifier>PF14749</identifier>
            <name>Acyl-CoA_ox_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisomal matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acyl-CoA dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acyl-CoA oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>FAD binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty-acyl-CoA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>flavin adenine dinucleotide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>palmitoyl-CoA oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>PDZ domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein N-terminus binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alpha-linolenic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid beta-oxidation using acyl-CoA dehydrogenase</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid beta-oxidation using acyl-CoA oxidase</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid oxidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>generation of precursor metabolites and energy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peroxisome fission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cholesterol homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spermatogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>unsaturated fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>very long-chain fatty acid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>